You are here

A Vaccine for Schistosomiasis, "SchistoShield"

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 2R44AI103983-06A1
Agency Tracking Number: R44AI103983
Amount: $1,719,617.00
Phase: Phase II
Program: SBIR
Solicitation Topic Code: NIAID
Solicitation Number: PA19-272
Solicitation Year: 2019
Award Year: 2020
Award Start Date (Proposal Award Date): 2020-03-13
Award End Date (Contract End Date): 2023-02-28
Small Business Information
Seattle, WA 98102-3788
United States
DUNS: 148051621
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 (206) 623-0331
Business Contact
Phone: (206) 714-2724
Research Institution

Schistosomiasis is a major parasitic disease which could impact up to a billion people in 74 countries. Current
control strategies rely primarily on anti-parasitic drugs alone (praziquantel) which has proven inadequate due to
both reinfection and the inherent threat of drug resistance. We have developed a potent schistosomiasis vaccine,
termed SchistoShield®, targeting a functionally important antigen (Sm-p80) formulated with a potent immune-
stimulator (GLA-SE). SchistoShield® has been exhaustively tested in rodents, rabbits, and baboons and has
exhibited protection at all parasitic life-cycle stages including larvae, worms, and egg laying, survival, and
excretion. We are completing our Phase II SBIR grant research focused on manufacture, lyophilization, and
fill/finish of the antigen and will be entering into three clinical trials (first an NIH funded Phase 1 human trial in
the USA, and next two Phase 1b trials funded by the European union which will be performed in Burkina Faso
and Madagascar in Africa) beginning in the first quarter of 2020.
To support our upcoming trials, this Phase IIb grant will focus on studies required to ensure stability of the vaccine
drug product (DP) for the duration of the trials as required by regulatory agencies. The research will include
assessing long-term stability, formal shipping studies, and development of a sensitive potency assay suitable for
later stage clinical development. The potency assay will include immunization into mice followed by antibody
titers after a single injection. We will forcibly degrade our antigen using simulated real-life conditions and test the
altered protein for retention of immunological function using our potency assay. The goal will be to identify which
quality parameters are directly indicative of a loss of potency.
At the end of these studies we will have our DP on stability, formal shipping methods identified, a sensitive
potency assay developed, and have identified critical quality parameters of potency of the vaccine. All these
studies are required in preparation for Phase 2 and 3 clinical trials and future licensure and deployment.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government